Cargando…
A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study
BACKGROUND: Venous thromboembolism is common in patients with cancer and requires anticoagulation with low molecular weight heparin. Current data informs anticoagulation as far as six months, yet guidelines recommend anticoagulation beyond six months in patients who have locally advanced or metastat...
Autores principales: | Smith, Joanna D, Baillie, Jessica, Baglin, Trevor, Griffiths, Gareth O, Casbard, Angela, Cohen, David, Fitzmaurice, David A, Hood, Kerenza, Rose, Peter, Cohen, Alexander T, Johnson, Miriam, Maraveyas, Anthony, Bell, John, Toone, Harold, Nelson, Annmarie, Noble, Simon I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003288/ https://www.ncbi.nlm.nih.gov/pubmed/24726032 http://dx.doi.org/10.1186/1745-6215-15-122 |
Ejemplares similares
-
Why do patients decline surgical trials? Findings from a qualitative interview study embedded in the Cancer Research UK BOLERO trial (Bladder cancer: Open versus Lapararoscopic or RObotic cystectomy)
por: Harrop, Emily, et al.
Publicado: (2016) -
Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins
por: Maraveyas, Anthony, et al.
Publicado: (2010) -
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
por: Seaman, Siwan, et al.
Publicado: (2014) -
Low molecular weight heparin and direct oral anticoagulants influence tumour formation, growth, invasion and vascularisation by separate mechanisms
por: Featherby, Sophie, et al.
Publicado: (2019) -
Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)